1
|
Albus A, Kronimus Y, Neumann S, Vidovic N, Frenzel A, Kuhn P, Seifert M, Ziehm T, van der Wurp H, Dodel R. Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β. Neuroscience 2021; 463:355-369. [PMID: 33958140 DOI: 10.1016/j.neuroscience.2021.03.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 03/01/2021] [Accepted: 03/02/2021] [Indexed: 02/08/2023]
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disease; thus, the search for a cure or causal therapy has become necessary. Despite intense research on this topic in recent decades, there is no curative therapy up today, and also no disease-modifying treatment has been approved. As promising approach passive immunization strategies have thereby come forth. In this study, we focused on naturally occurring autoantibodies against the AD-associated peptide amyloid-β. These antibodies have already reported to show beneficial functions in vitro and in mouse models of AD. However, their availability is limited due to their low abundance in peripheral blood. In a recent study, we were able to generate four recombinant antibodies against amyloid-β. In the present study, we tested these antibodies in ELISA and SPR assays for their binding behavior and by aggregation- and phagocytosis assays as functional evidences to characterize their amyloid-β-related neutralizing and clearance abilities. Further ex vivo assay on organotypic hippocampal slice cultures gave first evidence of microglial activation and inflammatory features. The tested recombinant antibodies in IgG format showed, in comparison to naturally occurring autoantibodies against amyloid-β, insufficient binding capacities and -affinities. However, after conversion of one antibody into a single chain format multimerization of the scFv-Fc construct, the investigated binding capacity and -affinity showed improvements. Further functional assays predict a protective effect of this antibody. Although, all four recombinant antibodies showed binding to amyloid-β, promising features were only detectable after conversion into a multimeric format. The multimeric scFv-Fc antibody exhibited thereby strong impact on amyloid-β clearance and inhibition of oligomerization.
Collapse
Affiliation(s)
- Alexandra Albus
- Chair of Geriatric Medicine, University Duisburg-Essen, Germany; Department of Neurology, Philipps-University, Marburg, Germany
| | - Yannick Kronimus
- Chair of Geriatric Medicine, University Duisburg-Essen, Germany; Department of Neurology, Philipps-University, Marburg, Germany
| | - Sascha Neumann
- Chair of Geriatric Medicine, University Duisburg-Essen, Germany
| | - Natascha Vidovic
- Chair of Geriatric Medicine, University Duisburg-Essen, Germany; Department of Neurology, Philipps-University, Marburg, Germany
| | | | | | - Marc Seifert
- Institute of Cell Biology (Cancer Research), Medical Faculty, University Duisburg-Essen, Germany
| | - Tamar Ziehm
- Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum Jülich, Jülich, Germany
| | - Hendrik van der Wurp
- Chair of Geriatric Medicine, University Duisburg-Essen, Germany; Faculty of Statistics, TU Dortmund University, Dortmund, Germany
| | - Richard Dodel
- Chair of Geriatric Medicine, University Duisburg-Essen, Germany; Department of Neurology, Philipps-University, Marburg, Germany.
| |
Collapse
|
2
|
Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein. PLoS One 2018; 13:e0202954. [PMID: 30157279 PMCID: PMC6114858 DOI: 10.1371/journal.pone.0202954] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2018] [Accepted: 08/13/2018] [Indexed: 12/21/2022] Open
Abstract
Background Abnormal aggregation of proteins induces neuronal cell loss in neurodegenerative disorders such as Alzheimer’s Disease, Creutzfeldt-Jakob Disease and Parkinson’s Disease. Specific stimuli initialize conformational changes in physiological proteins, causing intra- or extracellular protein aggregation. We and other groups have identified naturally occurring autoantibodies (nAbs) as part of the human antibody pool that are able to prevent peptide fibrillation. These nAbs show a rescue effect following exposure of toxic aggregates on neurons, and they support microglial uptake of aggregated peptides. Objective Identification of a putative common epitope among the relevant proteins β-Amyloid, α-Synuclein and Prion Protein for the respective nAbs. Material and methods Binding affinity between the aforementioned proteins and nAbs was tested by Dot Blot, ELISA and SPR-technology. Furthermore, the functionality of the protein-nAbs-complexes was studied in Thioflavin-T assays and microglial uptake experiments to study dependent inhibition of protein aggregation and enhancement of Fcγ mediated uptake by microglial cells. Results β-Amyloid and Prion Protein fragment showed considerable binding affinity and functional efficacy for all applied nAbs. Thereby, no significant difference within the different nAbs was detected. In contrast, α-Synuclein was bound exclusively by nAbs-α-Synuclein, which was reproduced in all binding studies. Surprisingly, functional assays with α-Synuclein revealed no significant effect of nAbs in comparison to IVIg treatment. However, all applied nAbs as well as IVIg show a minimal functionality on the microglial uptake of α-Synuclein. Conclusion nAbs-Aβ, nAbs-PrP possibly display comparable affinity to the same structural epitope within Aβ and PrP106-126 A117V whereas the epitope recognized by nAbs-α-Syn is only present in α-Syn. The structural similarity of Aβ and PrP fragment promotes the outline for an efficient antibody for the treatment of several neurodegenerative disorders and extend the functional characteristics of the investigated nAbs.
Collapse
|
3
|
Krestova M, Hromadkova L, Ricny J. Purification of Natural Antibodies Against Tau Protein by Affinity Chromatography. Methods Mol Biol 2018; 1643:33-44. [PMID: 28667528 DOI: 10.1007/978-1-4939-7180-0_4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Natural antibodies are now widely studied for their therapeutical potential. Therefore, their isolation and subsequent characterization is desired. Here, we describe an isolation method for natural anti-tau antibodies from human plasma by utilization of affinity chromatography with epoxy-activated copolymer resin. The evalution of isolation efficiency and avidity of isolated antibodies is decribed by modified indirect ELISA assay.
Collapse
Affiliation(s)
- Michala Krestova
- National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic.
| | - Lenka Hromadkova
- National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic
| | - Jan Ricny
- National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic
| |
Collapse
|
4
|
Chi B, Wang S, Bi S, Qin W, Wu D, Luo Z, Gui S, Wang D, Yin X, Wang F. Effects of ganoderic acid A on lipopolysaccharide-induced proinflammatory cytokine release from primary mouse microglia cultures. Exp Ther Med 2017; 15:847-853. [PMID: 29399089 PMCID: PMC5772755 DOI: 10.3892/etm.2017.5472] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Accepted: 08/24/2017] [Indexed: 01/13/2023] Open
Abstract
For several thousand years, Ganoderma lucidum (Ling-Zhi in Chinese and Reishi in Japanese) has been widely used as a traditional medication for the prevention and treatment of various diseases in Asia. Its major biologically active components, ganoderic acids (GAs), exhibit significant medicinal value due to their anti-inflammatory effects. Dysregulation of microglial function may cause seizures or promote epileptogenesis through release of proinflammatory cytokines, including interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α. At present, only little information is available on the effects of GAs on microglia-mediated inflammation in vitro and/or in vivo. The present study aimed to investigate the role of GA-A on microglia-mediated inflammation in vitro. In addition, the effect of GA-A on lipopolysaccharide (LPS)-evoked alterations in mitochondrial metabolic activity of microglia was evaluated. The results of the present study demonstrated that GA-A significantly decreased LPS-induced IL-1β, IL-6 and TNF-α release from mouse-derived primary cortical microglial cells in a concentration-dependent manner. GA-A treatment reduced LPS-induced expression of nuclear factor (NF)-κB (p65) and its inhibitor, demonstrating that non-toxic suppression of IL-1β, IL-6 and TNF-α production by GA-A is, at least in part, due to suppression of the NF-κB signaling pathway. In addition, the LPS-induced stimulation of mitochondrial activity of microglial cells was abolished by co-treatment with GA-A. Thus, GA-A treatment may be a potential therapeutic strategy for epilepsy prevention by suppressing microglia-derived proinflammatory mediators.
Collapse
Affiliation(s)
- Baojin Chi
- Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.,Department of Urology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China
| | - Shuqiu Wang
- Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China
| | - Sheng Bi
- Department of Urology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China
| | - Wenbo Qin
- Department of Urology, The Second Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China
| | - Dongmei Wu
- Material College, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China
| | - Zhenguo Luo
- Department of Urology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China
| | - Shiliang Gui
- Department of Urology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China
| | - Dongwei Wang
- Department of Urology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China
| | - Xingzhong Yin
- Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China
| | - Fangfang Wang
- Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China
| |
Collapse
|
5
|
Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo. PLoS One 2016; 11:e0161826. [PMID: 27561008 PMCID: PMC4999199 DOI: 10.1371/journal.pone.0161826] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 08/14/2016] [Indexed: 12/31/2022] Open
Abstract
In relation to the recent trials of Intravenous Immunoglobulin (IVIG) in Alzheimer’s Disease (AD) it was demonstrated that different IgG preparations contain varying amounts of natural anti-amyloid β (Aβ) antibodies as measured by ELISA. We therefore investigated the relevance of ELISA data for measuring low-affinity antibodies, such as anti-Aβ. We analysed the binding of different commercial Immunoglobulin G (IgG) preparations to Aβ, actin and tetanus toxoid in different binding assays to further investigate the possible cause for observed differences in binding to Aβ and actin between different IgG preparations. We show that the differences of commercial IgG preparations in binding to Aβ and actin in ELISA assays are artefactual and only evident in in vitro binding assays. In functional assays and in vivo animal studies the different IVIG preparations exhibited very similar potency. ELISA data alone are not appropriate to analyse and rank the binding capacity of low-affinity antibodies to Aβ or other endogenous self-antigens contained in IgG preparations. Additional analytical methods should be adopted to complement ELISA data.
Collapse
|
6
|
Wang T, Xie XX, Ji M, Wang SW, Zha J, Zhou WW, Yu XL, Wei C, Ma S, Xi ZY, Pang GL, Liu RT. Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin. Neuropharmacology 2016; 105:561-576. [PMID: 26907803 DOI: 10.1016/j.neuropharm.2016.02.015] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 02/07/2016] [Accepted: 02/15/2016] [Indexed: 11/25/2022]
Abstract
Alzheimer's disease (AD) is characterized by memory loss, intracellular neurofibrillary tangles, and extracellular plaque deposits composed of β-amyloid (Aβ). Previous reports showed that naturally occurring autoantibodies, such as intravenous immunoglobulin (IVIG), benefited patients with moderate-stage AD who carried an APOE-ε4 allele. However, the mechanism underlying the role of IVIG remains unclear. In this study, we identified naturally occurring autoantibodies against Aβ oligomers (NAbs-Aβo), which were purified by Aβ42 oligomer or Cibacron Blue affinity chromatography from IVIG and termed as Oli-NAbs and Blue-NAbs, respectively. Oli-NAbs and Blue-NAbs recognized Aβ42 oligomers or both Aβ40 and 42 oligomers, differently. Both antibodies inhibited Aβ42 aggregation and attenuated Aβ42-induced cytotoxicity. Compared with vehicles, Oli-NAbs, Blue-NAbs and IVIG significantly improved the memory and cognition, and reduced the soluble and oligomeric Aβ levels in APPswe/PS1dE9 transgenic mice. Further investigation showed that Blue-NAbs at increased doses effectively decreased plaque burden and insoluble Aβ levels, whereas Oli-NAbs significantly declined the microgliosis and astrogliosis, as well as the production of proinflammatory cytokines in vivo. Therefore, high levels of these antibodies against oligomeric Aβ40 or Aβ42 were required, correspondingly, to achieve the optimal effect. NAbs-Aβo could be condensed to a high concentration by affinity chromatography and its isolation from IVIG may not interfere with the normal function of conventional IVIG as its concentration is very low. Thus, the isolated NAbs-Aβo as an extra product of plasma required low cost and the enriched NAbs-Aβo may be more feasible than IVIG for the treatment of AD.
Collapse
Affiliation(s)
- Teng Wang
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; School of Life Science, AnHui Agricultural University, HeFei 230036, China
| | - Xi-Xiu Xie
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Mei Ji
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Shao-Wei Wang
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Jun Zha
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Wei-Wei Zhou
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Xiao-Lin Yu
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
| | - Chen Wei
- National Institutes for Food and Drug Control, Beijing 100050, China
| | - Shan Ma
- Shandong Institute of Biological Products, Taian 2710000, China
| | - Zhi-Ying Xi
- Shandong Institute of Biological Products, Taian 2710000, China
| | - Guang-Li Pang
- Shandong Institute of Biological Products, Taian 2710000, China.
| | - Rui-Tian Liu
- National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
| |
Collapse
|
7
|
He D, Liu CF, Chu L, Hao Z, Chen N, Liu F, Fang X, Tian T. Intravenous immunoglobulin for Alzheimer's disease. Hippokratia 2015. [DOI: 10.1002/14651858.cd011827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- Dian He
- The Second Affiliated Hospital of Soochow University, Soochow University; Department of Neurology; No 1055 Sanxiang Road Suzhou Jiangsu Province China 215004
- Affiliated Hospital of Guizhou Medical University; Department of Neurology; No. 28, Gui Yi Street Guiyang Guizhou Province China 550004
| | - Chun-feng Liu
- The Second Affiliated Hospital of Soochow University, Soochow University; Department of Neurology; No 1055 Sanxiang Road Suzhou Jiangsu Province China 215004
- Soochow University; Institute of Neuroscience; Suzhou China
| | - Lan Chu
- Affiliated Hospital of Guizhou Medical University; Department of Neurology; No. 28, Gui Yi Street Guiyang Guizhou Province China 550004
- Soochow University; Institute of Neuroscience; Suzhou China
| | - Zilong Hao
- West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041
| | - Ning Chen
- West China Hospital, Sichuan University; Department of Neurology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041
| | - Fang Liu
- Affiliated Hospital of Guizhou Medical University; Department of Neurology; No. 28, Gui Yi Street Guiyang Guizhou Province China 550004
| | - Xuming Fang
- Affiliated Hospital of Guizhou Medical University; Department of Neurology; No. 28, Gui Yi Street Guiyang Guizhou Province China 550004
| | - Tian Tian
- Affiliated Hospital of Guizhou Medical University; Department of Neurology; No. 28, Gui Yi Street Guiyang Guizhou Province China 550004
| |
Collapse
|
8
|
Feldman HH, Haas M, Gandy S, Schoepp DD, Cross AJ, Mayeux R, Sperling RA, Fillit H, van de Hoef DL, Dougal S, Nye JS. Alzheimer's disease research and development: a call for a new research roadmap. Ann N Y Acad Sci 2014; 1313:1-16. [PMID: 24754377 DOI: 10.1111/nyas.12424] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Epidemiological projections of the prevalence of Alzheimer's disease (AD) and related dementias, the rapidly expanding population over the age of 65, and the enormous societal consequence on health, economics, and community foretell of a looming global public health crisis. Currently available treatments for AD are symptomatic, with modest effect sizes and limited impact on longer term disease outcomes. There have been no newly approved pharmaceutical treatments in the last decade, despite enormous efforts to develop disease-modifying treatments directed at Alzheimer's-associated pathology. An unprecedented collaborative effort of government, regulators, industry, academia, and the community at-large is needed to address this crisis and to develop an actionable plan for rapid progress toward successfully developing effective treatments. Here, we map out a course of action in four key priority areas, including (1) addressing the fundamental mechanisms of disease, with the goal of developing a core set of research tools, a framework for data sharing, and creation of accessible validated and replicated disease models; (2) developing translational research that emphasizes rapid progress in disease model development and better translation from preclinical to clinical stages, deploying leading technologies to more accurately develop predictive models; (3) preventing AD through the development of robust methods and resources to advance trials and creating fundamental resources such as continuous adaptive trials, registries, data repositories, and instrument development; and (4) innovating public/private partnerships and global collaborations, with mechanisms to incentivize collaborations and investments, develop larger precompetitive spaces, and more rapid data sharing.
Collapse
Affiliation(s)
- Howard H Feldman
- Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Shin JI, Bayry J. Re: Kaiser: Emerging Therapies for Neovascular Age-related Macular Degeneration: Drugs in the Pipeline (Ophthalmology 2013;120:S11-S15). Ophthalmology 2014; 121:e21-2. [DOI: 10.1016/j.ophtha.2013.11.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2013] [Accepted: 11/05/2013] [Indexed: 11/17/2022] Open
|
10
|
Wuest DM, Lee KH. Amyloid-β concentration and structure influences the transport and immunomodulatory effects of IVIG. J Neurochem 2014; 130:136-44. [DOI: 10.1111/jnc.12678] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Revised: 01/25/2014] [Accepted: 01/28/2014] [Indexed: 01/06/2023]
Affiliation(s)
- Diane M. Wuest
- Department of Chemical and Biomolecular Engineering and Delaware Biotechnology Institute; University of Delaware; Newark Delaware USA
| | - Kelvin H. Lee
- Department of Chemical and Biomolecular Engineering and Delaware Biotechnology Institute; University of Delaware; Newark Delaware USA
| |
Collapse
|